Zürcher Nachrichten - Once-taboo ketamine booms for US at-home mental care

EUR -
AED 4.100273
AFN 78.60757
ALL 98.166966
AMD 432.286638
ANG 1.997847
AOA 1023.661719
ARS 1274.492205
AUD 1.739351
AWG 2.012159
AZN 1.902168
BAM 1.95574
BBD 2.26123
BDT 136.075794
BGN 1.958829
BHD 0.422187
BIF 3332.496993
BMD 1.116315
BND 1.454255
BOB 7.738761
BRL 6.322034
BSD 1.119965
BTN 95.745041
BWP 15.144532
BYN 3.665087
BYR 21879.783696
BZD 2.24963
CAD 1.559549
CDF 3204.942189
CHF 0.935299
CLF 0.027413
CLP 1051.967484
CNY 8.048081
CNH 8.048713
COP 4704.554582
CRC 567.282465
CUC 1.116315
CUP 29.582361
CVE 110.261592
CZK 24.899757
DJF 199.433835
DKK 7.461011
DOP 65.907963
DZD 148.865399
EGP 55.928271
ERN 16.744732
ETB 151.194627
FJD 2.537725
FKP 0.842071
GBP 0.840567
GEL 3.05914
GGP 0.842071
GHS 13.887571
GIP 0.842071
GMD 80.937172
GNF 9698.700213
GTQ 8.598734
GYD 234.312757
HKD 8.722499
HNL 29.141099
HRK 7.532941
HTG 146.54547
HUF 402.867531
IDR 18412.786848
ILS 3.96752
IMP 0.842071
INR 95.543378
IQD 1467.15465
IRR 47010.84053
ISK 145.891703
JEP 0.842071
JMD 178.534481
JOD 0.791807
JPY 162.594147
KES 144.755526
KGS 97.622219
KHR 4481.861466
KMF 492.857526
KPW 1004.660245
KRW 1561.859763
KWD 0.343145
KYD 0.933371
KZT 571.02235
LAK 24221.251321
LBP 100346.698283
LKR 335.109642
LRD 223.983077
LSL 20.217275
LTL 3.29619
LVL 0.675249
LYD 6.178809
MAD 10.389879
MDL 19.509397
MGA 5019.844837
MKD 61.528098
MMK 2343.870677
MNT 4001.744803
MOP 9.015121
MRU 44.32763
MUR 51.47373
MVR 17.25866
MWK 1941.939975
MXN 21.73009
MYR 4.795735
MZN 71.336723
NAD 20.217275
NGN 1788.71739
NIO 41.208726
NOK 11.593835
NPR 153.192265
NZD 1.897963
OMR 0.429497
PAB 1.119965
PEN 4.129072
PGK 4.654856
PHP 62.294316
PKR 315.375252
PLN 4.268489
PYG 8941.723611
QAR 4.081974
RON 5.106255
RSD 117.226377
RUB 90.497203
RWF 1603.750428
SAR 4.186446
SBD 9.31055
SCR 15.922308
SDG 670.351558
SEK 10.907859
SGD 1.452108
SHP 0.877249
SLE 25.344455
SLL 23408.578004
SOS 640.080215
SRD 40.8365
STD 23105.476908
SVC 9.799697
SYP 14514.229131
SZL 20.222375
THB 37.223582
TJS 11.546543
TMT 3.912686
TND 3.376696
TOP 2.614527
TRY 43.377235
TTD 7.596765
TWD 33.732379
TZS 3021.006621
UAH 46.488763
UGX 4097.873335
USD 1.116315
UYU 46.59856
UZS 14520.55117
VES 105.163869
VND 28936.572095
VUV 135.253884
WST 3.10171
XAF 655.936725
XAG 0.034565
XAU 0.000349
XCD 3.016899
XDR 0.815775
XOF 655.936725
XPF 119.331742
YER 272.496621
ZAR 20.143411
ZMK 10048.183034
ZMW 30.104069
ZWL 359.453134
  • CMSC

    -0.0500

    22.05

    -0.23%

  • SCS

    0.0000

    10.5

    0%

  • VOD

    0.1800

    9.45

    +1.9%

  • GSK

    0.4991

    37.64

    +1.33%

  • AZN

    0.8500

    68.81

    +1.24%

  • RBGPF

    64.5000

    64.5

    +100%

  • NGG

    1.2500

    71.28

    +1.75%

  • RYCEF

    0.0200

    10.72

    +0.19%

  • BTI

    1.2700

    42.64

    +2.98%

  • RIO

    -0.1100

    62.64

    -0.18%

  • CMSD

    0.0472

    22.06

    +0.21%

  • JRI

    0.1600

    12.9

    +1.24%

  • BCC

    0.9200

    91.91

    +1%

  • BCE

    -0.0700

    21.56

    -0.32%

  • RELX

    0.5300

    54.57

    +0.97%

  • BP

    0.1300

    29.76

    +0.44%

Once-taboo ketamine booms for US at-home mental care
Once-taboo ketamine booms for US at-home mental care

Once-taboo ketamine booms for US at-home mental care

Americans are paying to get a star of the psychedelic medicine movement –- ketamine -– shipped to them for at-home mental health treatments that are being called both a breakthrough and a gamble.

Text size:

A pandemic-spurred easing of prescription rules helped fuel a jump in telemedicine offerings of ketamine, an anesthetic that was once a taboo party drug but has become a buzzed-about tool against depression.

Yet long-term, large-scale studies of ketamine's medical impact are limited, leaving some experts concerned that an unregulated online boom could result in mishaps or a regulatory crackdown.

"This has to be rolled out slowly," said Boris Heifets, a Stanford University assistant professor of anesthesiology. "The risk is that we are scaling the fix but not the solution, which is a much more integrated approach to mental health."

Ketamine has been available in the United States since the 1970s as an anesthetic called a "dissociative" because of the hallucinogenic effects that have helped make it a rave culture drug.

It's legal for US doctors to prescribe, while some other psychedelics getting renewed attention for mental health uses like LSD or MDMA (also called ecstasy) are classified as having no medical utility and a high risk for abuse.

In this context, recent years have seen an uptick in clinics offering in-person intravenous ketamine treatments for depression, anxiety or chronic pain, though regulations and practices vary across American states.

- Ketamine 'babysitter' -

Then came the pandemic, which resulted in US authorities allowing doctors to remotely prescribe drugs like ketamine that previously required an in-person visit.

An increasing number of companies, some already doing in-clinic treatments, began offering to evaluate clients online and to send the drugs for home use to approved candidates.

Nue Life, which launched about a year ago, is one of those firms. Its CEO Juan Pablo Cappello estimated it has served over 3,000 ketamine patients so far.

"If you actually drill down on the sort of potentials for abuse here, you realize of course they exist, but we're creating a standard of care to make that quite unlikely," he told AFP.

For example, he noted clients are instructed to have an adult "babysitter" watch over them for the roughly 90 minutes the drug experience lasts, and he reasoned that people simply looking for ketamine could get it cheaper on the street.

Clients of the service, which costs $1,250 for a package providing six ketamine experiences, are encouraged but not obligated to couple it with therapy, Cappello said.

"The at-home telemedicine model, I would argue, is actually safer and more effective for patients," allowing more patients "to actually take advantage of these therapies," he added.

Heifets, the Stanford researcher, noted that making ketamine more available carries risks -- including the chances that authorities would tighten access if an at-home treatment resulted in some sort of tragedy.

- 'Change your life' -

US regulators in 2019 approved a type of ketamine specifically for adults with treatment-resistant depression, though with stringent rules like requiring patients to be monitored by a health care provider for at least two hours after their dose.

Americans have "a hair trigger for problem-solving through litigation," Heifets noted of the potential for lawsuits if things go wrong.

He was part of a team that analyzed the real-world effectiveness of intravenous ketamine therapy -- which can involve higher doses than the at-home services –- and reported most patients improved, though about eight percent said depressive symptoms worsened after treatment.

"We have very, very little evidence for our understanding of how effective ketamine is for depression at scale," he added.

Yet for people like 36-year-old New Yorker Philip Markle, who underwent an at-home treatment with a company called Mindbloom, ketamine is a profoundly useful tool.

Over his long battle with depression, the performer and comedian has tried medication, psychedelics like LSD, and talk therapy since the age of 12, but found something unique in ketamine.

Rather than the short-lived sense of change other treatments provided, ketamine imparted a sense of clarity and of helpful self-acceptance -– not the heavy effects he'd experienced with other psychedelics.

"It felt like if any drug could be administered through the mail, and you could do a psychedelic that could change your life, on your own, this would be the one," he told AFP.

L.Muratori--NZN